Altimmune
Open
$2.63
Prev. Close
$2.63
High
$2.63
Low
$2.60
Market Snapshot
$339.48M
-3.7
-1.34
$15K
57
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 57 full-time employees. The company went IPO on 2005-10-06. The firm is developing novel therapies for serious liver diseases. Its lead product candidate, pemvidutide (formerly ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, including reductions in liver fat, inflammation and fibrosis, whereas the activation of GLP-1 receptors mediates suppression of appetite and reduction of cravings as well as metabolic effects such as weight loss. The company has completed phase II development of pemvidutide. The company also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 57 full-time employees. The company went IPO on 2005-10-06. The firm is developing novel therapies for serious liver diseases. Its lead product candidate, pemvidutide (formerly ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, including reductions in liver fat, inflammation and fibrosis, whereas the activation of GLP-1 receptors mediates suppression of appetite and reduction of cravings as well as metabolic effects such as weight loss. The company has completed phase II development of pemvidutide. The company also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
Recently from Cashu
Novo Nordisk Launches Higher Dose Wegovy to Compete in Obesity Treatment Market
Wegovy’s Higher Dose Launch: A Strategic Response in the Obesity Market In a landscape increasingly dominated by effective obesity treatments, Novo Nordisk aims to reclaim its position with the upcomi…
Altimmune Reports Strong Q4 Earnings, Highlights Strategic Growth and Clinical Advancements
### Altimmune Reports Strong Earnings and Strategic Initiatives at Q4 Earnings Call Altimmune (NASDAQ:ALT) announces notable financial growth as it reports its fourth-quarter earnings, showcasing a su…
Altimmune Reports Strong Growth and Pipeline Developments Amid Biotechnology Market Dynamics
Altimmune’s Strategic Growth and Pipeline Advancements Take Center Stage Altimmune, a key player in the biotechnology sector, announces substantial developments in its financial performance during its…
Altimmune's Pemvidutide Receives Breakthrough Therapy Designation for Innovative Obesity Treatment
Altimmune Secures Breakthrough Therapy Designation for Pemvidutide, Paving the Way for Innovative Obesity Treatment Altimmune, Inc. (NASDAQ:ALT) reaches a significant milestone with the U.S. Food and…